Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gigacloud Technology Inc (GCT) vs Novo Nordisk A/S (NVO) Price & Performance

Gigacloud Technology IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Gigacloud Technology Inc vs Novo Nordisk A/S — how do they compare? Gigacloud Technology Inc trades at $51.47 (market cap $1.84B), while Novo Nordisk A/S trades at $46.25 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 113× Gigacloud Technology Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.

GCTNVO
Market Cap
$1.84B$207.85B
Sector
TechnologyHealth
52-Week High
$53.25$63.98
52-Week Low
$25.44$35.29
Enterprise Value
$1.97B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gigacloud Technology Inc

GCT trades at $51.25, down 0.78% on the day, with strong technical momentum showing bullish moving averages and key resistance at $53. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.16 beating estimates by 29%, maintaining consistent earnings beats and 10.65% net margins. Revenue growth accelerated to 28% in Q2 2026, reaching $1.5B annually, while cash flow generation remains healthy at $120M net cash flow for 2025.

GCT presents a compelling growth story with attractive valuation at 12.25 P/E ratio and strong analyst support (67% buy ratings). Key risks include competitive pressures in furniture logistics and potential margin compression from expansion costs. The stock's technical overbought condition (RSI above 84) suggests near-term consolidation may precede further upside driven by execution on European expansion and New Classic integration.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gigacloud Technology Inc

Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.

Read more on GCT

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO